GSK says senior executives appear to have broken Chinese law
LONDON/SHANGHAI | Mon Jul 22, 2013 11:58am BST
(Reuters) - British drugmaker GlaxoSmithKline said on Monday that some of its executives in China appeared to have broken the law in a bribery scandal while proposed changes to the firm's business model would lower the cost of its medicine in the country.
GSK is the latest in a string of multinationals to be targeted by Chinese authorities over alleged corruption, price-fixing and quality controls.